Recent Winners

Alert Price: $0.36
High Price: $1.01
Results: 180% in 40 Days
Alert Price: $1.81
High Price: $4.65
Results: 157% in 36 Days
Alert Price: $1.50
High Price: $3.50
Results: 133% in 85 Days
Alert Price: $15.85
High Price: $30
Results: 91% in 41 Days
Alert Price: $1.40
High Price: $2.66
Results: 90% in 69 Days
Alert Price: $12.72
High Price: $23.75
Results: 87% in 20 Days
Alert Price: $10.10
High Price: $17.38
Results: 72% in 51 Days
Alert Price: $37.68
High Price: $61.73
Results: 64% in 67 Days
Alert Price: $28.22
High Price: $44.46
Results: 58% in 60 Days
Alert Price: $1.47
High Price: $2.32
Results: 58% in 29 Days
Alert Price: $15.10
High Price: $23.40
Results: 55% in 37 Days
Alert Price: $1.20
High Price: $1.76
Results: 47% in 60 Days
Alert Price: $25.06
High Price: $36.40
Results: 45% in 67 Days
Alert Price: $79.39
High Price: $114.06
Results: 44% in 51 Days
Alert Price: $18.24
High Price: $25.09
Results: 38% in 55 Days
Alert Price: $48.25
High Price: $65.90
Results: 36% in 28 Days
Alert Price: $13.75
High Price: $18.50
Results: 35% in 51 Days
Alert Price: $27.22
High Price: $35.88
Results: 32% in 6 Days
Alert Price: $37.05
High Price: $48.42
Results: 31% in 68 Days
Alert Price: $134.56
High Price: $171.52
Results: 27% in 55 Days
Alert Price: $13.40
High Price: $17.04
Results: 27% in 22 Days
Alert Price: $55.67
High Price: $70.64
Results: 27% in 73 Days
Alert Price: $1.58
High Price: $1.98
Results: 25% in 72 Days
Alert Price: $70.05
High Price: $87.41
Results: 25% in 61 Days
Alert Price: $4.43
High Price: $5.45
Results: 23% in 3 Days
Alert Price: $8.30
High Price: $10.25
Results: 23% in 12 Days
Alert Price: $15.40
High Price: $18.67
Results: 21% in 11 Days
Alert Price: $6.89
High Price: $8.25
Results: 20% in 11 Days
Alert Price: $4.49
High Price: $5.37
Results: 20% in 62 Days
Alert Price: $11.24
High Price: $13.46
Results: 20% in 15 Days
Alert Price: $63.23
High Price: $76.06
Results: 20% in 68 Days

Past results are not indicative of future profits. This table is accurate, though not every trade is represented.



Trading Lessons

Mainstream Financial News


Immunogen Pops On Leerink Partners Upgrade

April 19, 2017: Immunogen’s stock popped 13% today on an upgrade from Leerink Partners. Leerink Partners raised Immunogen to an Outperform rating, from Market Perform, and set a price target of $8. Leerink Partners is upgrading Immunogen based on their higher level of conviction on lead asset mirvetuximab soravtansine providing an attractive risk/reward in context (Read More….)

Sell Cancer Genetics For an Awesome 133% Win!

April 16, 2017: Sell Cancer Genetics for an incredible 133% win in 85 days and congratulations if you made money on the trade.

December 9, 2016: H.C. Wainwright/ Rodman & Renshaw reiterates a Buy rating on Cancer Genetics, and sets a price target of $6.

December 7, 2016: Cancer Genetics announced a collaboration with BeiGene, (Read More….)

Halozyme Therapeutics FDA Advisory Committee Voted 11 to 0 for Rituximab/Hyaluronidase

March 29, 2017: Halozyme Therapeutics announced that an Oncologic Drug Advisory Committee of the U.S. Food and Drug Administration voted 11 to 0 that the benefit/risk of rituximab/hyaluronidase for subcutaneous (under the skin) injection was favorable for patients in the proposed indications of follicular lymphoma, diffuse large B-cell lymphoma and chronic lymphocytic leukemia. The FDA (Read More….)

Top Performing GuerillaStockTrading Stocks For the Week Ending March 3 2017

GBT exploded into position #1 gaining 31% last week. Nomura initiated coverage of GBT with a Buy rating and a price target of $50. Let’s go ahead and book profits on Monday if you haven’t already. Remember folks, sell into strength and don’t wait for me to issue a sell signal before cashing out and (Read More….)

Sell Exact Sciences For a 55% Win!

March 4, 2017: Sell Exact Sciences for a 55% win in 37 days. Congratulations if you were able to make money on the trade and always remember to sell your positions before you get the sell alert from me. I review more than 200 open stock positions over the weekend when I have time and (Read More….)

Actinium Pharmaceuticals Expands IP Portfolio

February 28, 2017: Actinium Pharmaceuticals announced that they received a notice of allowance from the United States Patent and Trademark Office (USPTO) for a patent claiming the methods for generating a radioimmunoconjugate comprised of actinium-225, an alpha emitting radioisotope, conjugated to monoclonal antibodies. Actinium-225 is the radioisotope used in Actinium’s Actimab-A, a drug candidate in (Read More….)

CRISPR’s Brave New World

Just a handful of technologies deserve to be called “game changers”—and CRISPR-Cas9, the new gene-editing tool, is one of them. Discovered just three years ago, CRISPR is sweeping through labs around the world and researchers are already using it to experiment on diseases like cancer and AIDS, engineer new sources of clean energy, and create (Read More….)

Wells Fargo Gives Buy On Juno One Day, Downgrades the Next!

February 23, 2017: Wells Fargo initiated coverage of JUNO on February 22, 2017 with an Outperform rating. Then, one day later on February 23, 2017, Wells Fargo downgraded JUNO to market perform! Was this a rotational dump at $24 and we just provided Wells Fargo the liquidity they needed? I don’t know but my trust (Read More….)

CAR-T Cells Destroying Glioblastoma Cells

Glioblastoma is a malignant and rapidly growing astrocytoma of the central nervous system and usually is detected in the brain. Glioblastoma is the worst grade of malignant glioma, a relatively uncommon but deadly class of brain tumors that kills 97% of those diagnosed within 5 years.

Below is a video of CAR-T cells destroying glioblastoma (Read More….)

MD Anderson’s CAR T-cell Patient

CAR-T cell therapy to cure cancer is a big deal folks. Unfortunately it’s still in clinical trials and then the cost of producing individual CAR-T cells for a specific patient is extremely high. Nevertheless advances are being made in mass producing CAR-T cells that everyone can use like what Cellectis is doing.

Check out this (

Celgene Announces Positive Results from Phase III Trial of Oral Ozanimod

February 17, 2017: Celgene announced that its phase III SUNBEAM trial, evaluating the efficacy and safety of ozanimod, an investigational oral, selective S1P 1 and 5 receptor modulator, in patients with relapsing multiple sclerosis (RMS), met the primary endpoint in reducing annualized relapse rate (ARR), compared to weekly interferon (IFN) ß-1a (Avonex).

SUNBEAM evaluated two (

Cellectis Gets Investigational New Drug Approval From FDA For Phase 1 Trials With UCART123

February 6, 2017: Cellectis announced that it has received an Investigational New Drug approval from the FDA to conduct Phase 1 clinical trials with UCART123, the Company’s most advanced, wholly owned TALEN gene-edited product candidate, in patients with acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm (BPDCN). This marks the first allogeneic, “off-the-shelf” (Read More….)

Regeneron Pharmaceuticals Gets Approval of Kevzara With Sanofi For Rheumatoid Arthritis

February 1, 2017: Regeneron Pharmaceuticals, Inc. and Sanofi today announced that Health Canada approved Kevzara™ (sarilumab), an interleukin-6 (IL-6) receptor antibody, for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response or intolerance to one or more biologic or non-biologic Disease-Modifying Anti-Rheumatic Drugs (DMARDs).

Kevzara (

Top Performing Stocks On GuerillaStockTrading For Week Ending January 27 2017

OREX continues to be our dominant stock pick up a whopping +80% since profiled on

The biggest new gainer this last week was PLX which rocketed higher after it received FDA Orphan Drug Designation for CTP-656 for the treatment of Cystic Fibrosis.

Another big climber was CGIX after it launched its entry into comprehensive (Read More….)

Aratana Therapeutics Transiting From R&D To Revenue Producing Company

January 27, 2017: Aratana Therapeutics hot stock tip sent in through GuerillaStockTrading website. The catalyst is that with four FDA approvals for dogs, the company is transitioning from an R&D company to a revenue producing company this year. Thank you for sending in this hot stock tip with the catalyst.

January 24, 2017: Elanco Animal (

CTI BioPharma FDA Hold Removed and Positive PERSIST-2 Phase 3 Data

January 7, 2017: Biotechnology firm CTI BioPharma announced on January 4, 2017 that the full clinical hold (February 2016) implemented by the U.S. Food and Drug Administration (FDA) on all clinical trials conducted under the Investigational New Drug (IND) application for pacritinib has now been removed. The Company’s complete response submission included, among other items, (Read More….)

Seattle Genetics Sell For Loss After Deaths Of Phase 1 Trial

December 27, 2016: Seattle Genetics announced that it has received notice from the U.S. Food and Drug Administration (FDA) that a clinical hold or partial clinical hold has been placed on several early stage trials of vadastuximab talirine (SGN-CD33A) in acute myeloid leukemia (AML). The clinical holds were initiated to evaluate the potential risk of (Read More….)

Moonshot In Agenus Checkpoint Antibody INCAGN1949

December 14, 2016: Agenus is a high-risk biotechnology moonshot play on the clinical trial of anti-OX40 checkpoint antibody INCAGN1949 in patients with solid tumors. On November 30, 2016, Agenus announced that the first patient has been dosed in a Phase 1/2 clinical trial of the anti-OX40 agonist antibody INCAGN1949. The trial is being conducted by, (Read More….)